Tobacco Companies Are Cashing In on Zyn’s Unstoppable Popularity
Tobacco companies are racing to capitalize on the surging popularity of Zyn and other smoke-free alternatives.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Tobacco firms are actively seeking to profit from the widespread growth of Zyn. This shift toward smoke-free products is notably occurring as companies like Philip Morris seek success with both regulators and investors.
Coverage from The New York Times and Barron's emphasizes the financial race to cash in on Zyn's popularity and the market appeal of non-combustible products. Meanwhile, Oncodaily features perspectives from Lisa A.
Lacasse regarding the FDA's role in protecting public health versus the profit margins of big tobacco. Future developments center on whether Philip Morris' smoke-free products continue to win over regulators and investors, and how the FDA manages the balance between public health and industry profitability.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
Which companies are mentioned in relation to smoke-free products?
Philip Morris is specifically cited as having smoke-free products that are winning with regulators and investors.
What is the primary driver of the current industry trend?
The unstoppable popularity of Zyn is driving tobacco companies to find ways to cash in.
What is the critique regarding the FDA's role in this trend?
According to Lisa A. Lacasse in Oncodaily, the FDA's objective should be protecting public health rather than expanding the profit margins of big tobacco.
Coverage (4)
- Zyn’s Popularity Has Tobacco Companies Racing to Cash In NYT > Business · 4h ago
- Lisa A. Lacasse։ The FDA’s Job is to Protect Public Health, Not Expand the Profit Margins of Big Tobacco Oncodaily · 4h ago
- Philip Morris’ Smoke-Free Products Are Winning With Regulators. They’ll Win With Investors Too. Barron's · 4h ago
- Tobacco Companies Are Cashing In on Zyn’s Unstoppable Popularity The New York Times · 4h ago broke it first
People, places & organizations
Topics
Related trends
The New Rules of Sunscreen
The U.S. sunscreen market is shifting toward clinical necessity following the FDA's first approval of a new active ingredient in decades.
Potato chip recall upgraded to highest FDA risk level over salmonella concerns
The FDA has upgraded a potato chip recall involving brands like Utz Zapp's and Dirty to Class I, its highest risk level, due to salmonella concerns.
Exclusive: FDA allows ZYN to sell pouches on health benefits
The FDA has granted Philip Morris permission to market ZYN nicotine pouches as a safer, lower-risk alternative to cigarettes.
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
The FDA has launched a new initiative to accelerate the review process for new pharmaceutical manufacturing facilities.
Supplements sold online through major retailers recalled nationwide over potential salmonella risk
Major online retailers are recalling TNVitamins moringa powder supplements nationwide due to potential salmonella contamination.
Nearly 1 million bottles of heart and kidney medication recalled over foreign substance found on tablets
Nearly 1 million bottles of heart and kidney medications have been recalled nationwide due to the discovery of foreign substances on the tablets.